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COSTING METHODOLOGY ISSUES
CM'
ESTIMATING THE COSTS AND OUTCOMES
FOR DIFFERENT DISEASE MANAGEMENT
STRATEGIES: A CASE STUDY OF
CYTOMEGALOVIRUS INFECTION
AND DISEASE
Mauskopf y. Annemans 12. Richter N. Chulay J3, Maclaine Gl
'Research Triangle Institute, Research Triangle Park, NC, USA;
2HEDM, Belgium; lGlaxo Wellcome, Research Triangle Park,
NC, USA
This workshop will describe a methodology for estimat-
ing the costs and outcomes for a disease under different
disease management strategies. The methodology uses a
combination of published data, physician interviews, na-
tional databases, and standard reference sources and can
be applied in multiple countries. The methodology in-
cludes several steps including: (l) a review of the pub-
lished literature on disease epidemiology, treatment and
prevention efficacy, and disease management recommen-
dations; (2) interviews with physicians managing the dis-
ease to determine their treatment practices and to ask
them about the health care products and services used by
their patients; (3) use of standard references and national
data bases to validate the health care use data and to ob-
tain unit costs for health care services; (4) validation of
the results using patient data bases; and (5) combination
of all the data using spreadsheet and decision tree soft-
ware. The methodology will be illustrated using the ex-
ample of cytomegalovirus (CMV) infection and disease in
renal transplant patients. Three disease management
strategies are compared, prophylaxis (ganciclovir), testing
for virus (direct antigen testing and culture) and preemp-
tive therapy (ganciclovir), and treatment only (ganciclovir
with or without immune globulin). The cost and outcome
estimates were obtained for the US and the UK. The re-
sults can be applied by health care decision makers and
providers to understand the impact of different current
and anticipated disease management strategies on costs
and patient outcomes.
CM2
CLINICAL INTERVENTION ASSESSMENT:
IMPLEMENTATION OF DEFAULT VALUES FOR
EXPEDITING THE CALCULATION OF COST
SAVINGS AND COST AVOIDANCES
Mutnick A. Sterba K. Vrchoticky T
University of Iowa Hospitals and Clinics, Iowa City, fA, USA
Our Pharmacy department has previously described the
implementation of a clinical documentation system. This
computerized system is utilized by pharmacists in both
the inpatient and ambulatory care practices throughout
our institution, and allows for the comprehensive docu-
mentation of clinical activities. A major goal of the sys-
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tem is to accurately capture cost avoidances as well as
cost savings attributed to our staff through their day to
day interactions with the patients whom they serve. The
method utilized for calculating cost avoidances as previ-
ously been described, relies on hospital-specific DRG
data as a proxy in order to better quantify the impact of
our clinical interventions on the patients' length of stay.
During the initial 5,000 interventions, a series of weekly
meetings was initiated where clinical as well as adminis-
trative staff met to manually review interventions in or-
der to quantify cost savings as well as cost avoidances.
However, a significant rate limiting step for the process
was the amount of time necessary to accurately evaluate
the numerous interventions. Currently, more then 40,000
interventions have been entered into our electronic data-
base. The growing numbers of interventions docu-
mented have necessitated the development of a series of
drug specific defaults which allow for the automatic cal-
culation of cost savings and cost avoidances based on our
historical data. This method (1) offers a more streamlined
approach to the calculation of these important outcome
data; (2) decreases the time required by the financial as-
sessment committee to evaluate the economic impact of
clinical interventions; and (3) provides a more cost-effec-
tive method of obtaining this important data to provide
to hospital administrators, clinical decision makers, and
department staff.
CM~
MULTIVARIABLE METHODS FOR MEASURING
TREATMENT COSTS IN RANDOMIZED TRIALS
Polsky D. Glick H
University of Pennsylvania, Philadelphia, PA, USA
As treatment costs are increasingly determined from indi-
vidual level cost data, the number of proposed multivari-
able methods for use in this analysis has multiplied. These
methods involve estimation of multivariable cost func-
tions that yield predictions at the individual level, condi-
tional on interventions, patient characteristics, and other
factors. What are these methods, how are they used prop-
erly, and what are the circumstances when one method is
preferred over others? The purpose of this workshop will
be to develop skills in conducting multivariable analysis
of cost data from randomized trials. We will instruct par-
ticipants in the use of ordinary least squares regression
techniques and survival analysis techniques. We will dis-
cuss how non-normal cost data and censored cost data
are properly and improperly handled in these methods.
Participants will learn when it is appropriate to use log
transformation of costs in their analysis and how to esti-
mate unbiased treatment costs using smearing techniques.
Participants will also learn how to apply the Cox propor-
tional hazard model to analysis of costs. How does one
determine which model is best given the circumstances?
We will develop concepts important for evaluating the
superior model: predictive validity and adherence to as-
sumptions for unbiased estimators. We will present re-
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sults from a simulation designed to evaluate how well the
various methods perform under different circumstances.
Those who want to learn the techniques of multivariable
cost analysis and develop criteria for choosing the best
technique will benefit from this workshop. Participants
who would benefit include analysts of cost data and those
who want to increase their understanding of the literature
of economic evaluation.
CM.
USE OF UB·92S AND MEDICARE COST REPORTS
IN A LARGE, MULTI-CENTER RANDOMIZED
TRIAL: THE PURSUIT EXPERIENCE
Davidson-Ray LI, Buell HI, O'Neal BI, McElwee N2, Mark OBI
'Duke Clinical Research Institute, Durham, NC, USA; -Schering-
Plough Corp., Kenilworth, NJ, USA
The conversion of hospital bill charges using Uniform Bill
(UB)-92s and Medicare Ratios of Cost to Charges
(RCCs) to costs in economic analyses is one of the most
efficient, accurate and accessible ways of measuring re-
source consumption for US hospitalizations.
OBJECTIVES: We used the hospital bill charge to cost
conversion method in our analysis of over 3,000 patients
with 4,700 hospital bills in the recently completed PUR-
SUIT pharmacoeconomic substudy. Using the PURSUIT
trial experience as a model, this workshop will provide a
detailed explanation of the cost to charge conversion
methodology. We will begin with a detailed procedure
for incorporating this method of cost collection into a
clinical trial's overall protocol and case report form. We
will explain how to ensure collection of bills for all pa-
tient hospitalizations and procedures; how to interpret
the UB-92; how to extract charges from the UB-92 and
convert those charges into costs using each hospital's
Medicare Ratio of Cost to Charges. This workshop will
also explore mechanisms for ensuring successful compli-
ance across sites in large, randomized clinical trials in-
cluding inservice training for coordinators and common
obstacles to successful and complete collection. In addi-
tion, the workshop will explore the limitations and
strengths of this method compared with other cost collec-
tion methods. This workshop will be particularly useful
to project leaders, clinical trial coordinators, and database
managers interested in performing economic analyses as
part of larger clinical trials or as stand-alone endeavors.
CMS
DISCOUNTING HEALTH BENEFITS IN
PHARMACOECONOMIC ANALYSES:
IS IT JUSTIFIED?
Caro JJ, Klittich WS
Caro Research, Boston, MA, USA
Most guidelines for economic analysis call for discount-
ing of health benefits. This major methodological point
has rapidly moved from debate to common practice. Yet,
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the powerful effect that discounting can have on an anal-
ysis means that it may become the dominant factor in a
therapeutic decision. These grave implications should
cause pharmacoeconomic analysts to take pause. This
workshop will examine the implications of discounting,
its rationale and counterpoints, in an effort to establish
whether discounting of benefits is justified or not. Topics
covered will be: The Basis for Discounting; The Logical
Implications of Discounting; and Discounting: A New
Approach. Pharmacoeconomics is a fast evolving field.
New thought should continually be put into refining its
methodology. Ultimately, the aim of this workshop is to
take time to rethink the various issues that surround dis-
counting of health benefits.
CM.
THE USE OF PATIENT SELF-REPORTS TO
COLLECT HEALTH CARE RESOURCE
UTILIZATION DATA
Crawford BI, Evans C2
'Charles RiverAssociates, Boston, MA, USA; -Astra USA,
Westborough, MA, USA
This workshop offers a critical examination of the use of
patient self-reports in pharmacoeconomic evaluations.
This session is directed at individuals in pharmaceutical
firms, CROs, and consultancy companies who are re-
sponsible for the design and conduct of pharrnacoeco-
nomic evaluations. The workshop advances recent re-
search by concentrating on how the method of data
collection in prospective clinical economic evaluations
may influence study findings. Scant attention has been
paid to the fact that the high level of internal validity
found in prospective studies may be compromised by the
application of inappropriate methodologies to data col-
lection. Particular attention in this workshop is placed on
how validity may be affected by the elapsed time between
admission and self-reporting, salience of a treatment
event and perceived social desirability of a condition. As
part of this workshop we will highlight areas where esti-
mates based on patient self-reports lead to either reliable
or suspect values. In particular, we examine the areas of
hospitalization, outpatient consultations, medication use
and indirect costs. The impact that patient self-reports
have on cost-effectiveness ratios is also discussed. Attend-
ees at this workshop will gain an understanding of cur-
rent methodological shortcomings in this area and re-
searchers and readers of pharmacoeconomic studies will
gain the skills necessary to better design studies and eval-
uate the validity of, and potential for bias in cost-effec-
tiveness analyses.
